- Home
- SLN vs CATX Comparison
SLN vs CATX Comparison
Compare SLN & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- CATX
- Stock Information
- Founded
- SLN 1994
- CATX 1983
- Country
- SLN United Kingdom
- CATX United States
- Employees
- SLN N/A
- CATX N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- CATX Medical/Dental Instruments
- Sector
- SLN Health Care
- CATX Health Care
- Exchange
- SLN Nasdaq
- CATX Nasdaq
- Market Cap
- SLN 268.8M
- CATX 239.0M
- IPO Year
- SLN N/A
- CATX N/A
- Fundamental
- Price
- SLN $6.59
- CATX $4.76
- Analyst Decision
- SLN Buy
- CATX Strong Buy
- Analyst Count
- SLN 6
- CATX 11
- Target Price
- SLN $39.67
- CATX $13.00
- AVG Volume (30 Days)
- SLN 115.5K
- CATX 1.1M
- Earning Date
- SLN 11-13-2025
- CATX 11-11-2025
- Dividend Yield
- SLN N/A
- CATX N/A
- EPS Growth
- SLN N/A
- CATX N/A
- EPS
- SLN N/A
- CATX N/A
- Revenue
- SLN $27,169,000.00
- CATX $1,235,000.00
- Revenue This Year
- SLN N/A
- CATX N/A
- Revenue Next Year
- SLN N/A
- CATX N/A
- P/E Ratio
- SLN N/A
- CATX N/A
- Revenue Growth
- SLN 22.28
- CATX N/A
- 52 Week Low
- SLN $1.97
- CATX $1.60
- 52 Week High
- SLN $19.36
- CATX $13.19
- Technical
- Relative Strength Index (RSI)
- SLN 69.56
- CATX 69.03
- Support Level
- SLN $5.00
- CATX $4.66
- Resistance Level
- SLN $5.83
- CATX $5.39
- Average True Range (ATR)
- SLN 0.41
- CATX 0.35
- MACD
- SLN 0.16
- CATX 0.16
- Stochastic Oscillator
- SLN 93.42
- CATX 69.48
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.